Concepedia

Publication | Open Access

The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial

DOIFull Paper Access

15

Citations

20

References

2024

Year

Ron T. Gansevoort, David C. Wheeler, Francisco Martínez Debén, Marijn M. Speeckaert, Dirk Thomas, Mario Berger, Stefan Klein, Frauke Friedrichs, Karen Paraschin, Roland E. Schmieder
Nephrology Dialysis Transplantation

Abstract

Runcaciguat improved albuminuria in patients with CKD, irrespective of concomitant SGLT2i. Runcaciguat was well tolerated. sGC activation may represent a novel kidney-protective treatment in CKD patients (funded by Bayer AG; ClinicalTrials.gov number, NCT04507061).

References

YearCitations

Page 1